Melanoma biomarkers: Vox clamantis in deserto (Review)
- Authors:
- Mays Al-Shaer
- Divya Gollapudi
- Chris Papageorgio
-
Affiliations: Department of Internal Medicine, University of Missouri, Columbia, MO 65203, USA - Published online on: May 1, 2010 https://doi.org/10.3892/ol_00000070
- Pages: 399-405
This article is mentioned in:
Abstract
|
Biomarkers Definitions Working group. Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clin Pharmacol Ther. 69:89–95. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Beastall GH, Cook B, Rustin GJS and Jennings J: A review of the role of established tumor markers. Ann Clin Biochem. 28:5–18. 1991. View Article : Google Scholar | |
|
Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 19:3635–3648. 2001.PubMed/NCBI | |
|
Gershenwald JE, Thompson W, Mansfield PF, et al: Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 17:976–983. 1999. | |
|
White RR, Stanley WE, Johnson JL, Tyler DS and Seigler HF: Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg. 235:879–887. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Barth A, Wanek LA and Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 181:193–201. 1995.PubMed/NCBI | |
|
Manola J, Atkins M, Ibrahim J, et al: Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 18:3782–3793. 2000.PubMed/NCBI | |
|
Bowen GM, Chang AE, Lowe L, et al: Solitary melanoma confined to the dermal and/or subcutaneous tissue: evidence for revisiting the staging classification. Arch Dermatol. 136:1397–1399. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Karakousis CP, Velez A, Driscoll DL and Takia H: Mastectomy in malignant melanoma. Surgery. 115:295–302. 1994. | |
|
Eton O, Legha SS, Moon TE, et al: Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol. 16:1103–1111. 1998.PubMed/NCBI | |
|
Allen IE, Kupelnick B, Kumashiro M, et al: Efficacy of interleukin-2 in the treatment of metastatic melanoma: systematic review and meta-analysis. Cancer Ther. 1:168–173. 1998. | |
|
Bedikian AY, Johnson MM, Warneke CL, et al: Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest. 26:624–633. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Balch CM, Wilkerson JA, Murad TM, et al: The prognostic significance of ulceration of cutaneous melanoma. Cancer. 45:3012–3017. 1980. View Article : Google Scholar : PubMed/NCBI | |
|
McGovern VJ, Shaw HM, Milton GW, et al: Ulceration and prognosis in cutaneous malignant melanoma. Histopathology. 6:399–407. 1982. View Article : Google Scholar : PubMed/NCBI | |
|
Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factor analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 19:3622–3634. 2001.PubMed/NCBI | |
|
Buzaid AC, Ross MI, Balch CM, et al: Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 15:1039–1051. 1997.PubMed/NCBI | |
|
Cascinelli N, Belli F, Santinami M, et al: Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol. 7:469–474. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P and Cascinelli N: Prognostic value of tumor infiltrating lymphocytes in vertical growth phase of primary cutaneous melanoma. Cancer. 77:1303–1310. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Mihm MC Jr, Clemente CG and Cascinelli N: Tumor infiltrating lymphoctyes in lymph node mlelanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest. 74:43–47. 1996.PubMed/NCBI | |
|
Healy E, Belgaid C, Takata M, et al: Prognostic significance of allelic losses in primary melanoma. Oncogene. 16:2213–2218. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Brochez L and Naeyaert JM: Serological markers for melanoma. Br J Dermatol. 143:256–268. 2000. View Article : Google Scholar | |
|
Sirott MN, Bajorin DF, Wong GY, et al: Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer. 72:3091–3098. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Finck SJ, Giuliano AE and Morton DL: LDH and melanoma. Cancer. 51:840–843. 1983. View Article : Google Scholar : PubMed/NCBI | |
|
JaÈckel A, Deichman M, Waldmann V, et al: S-100b protein in serum, a tumor marker in malignant melanoma current state of knowledge and clinical experiences. Hautarzt. 50:250–256. 1999.PubMed/NCBI | |
|
Molina R, Navarro J, Filella X, Castel T and Ballesta AM: S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol. 23:39–44. 2002. View Article : Google Scholar | |
|
Hauschild A, Michaelsen J, Brenner W, et al: Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res. 9:155–161. 1999. View Article : Google Scholar | |
|
Hauschild A, Engel G, Brenner W, et al: S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology. 56:338–344. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Bonfrer JMG, Korse CM and Israels SP: Serum S-100 has prognostic significance in malignant melanoma. Anticancer Res. 17:2975–2978. 1997.PubMed/NCBI | |
|
Mocellin S, Zavagno G and Nitti D: The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer. 123:2370–2376. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Garbe C, Leiter U, Ellwanger U, et al: Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer. 97:1737–1745. 2003. View Article : Google Scholar | |
|
Medic S, Pearce RL, Heenan PJ and Ziman M: Molecular markers of circulating melanoma cells. Pigment Cell Res. 20:80–91. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kaskel P, Berking C, Sander S, et al: S-100 protein in peripheral blood: a marker for melanoma metastases. J Am Acad Dermatol. 41:962–969. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Von Schoultz E, Hansson LO, Djureen E, et al: Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res. 6:133–137. 1996. | |
|
Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J and Klingmuller D: Clinical significance of serum S 100 in metastatic malignant melanoma. Eur J Cancer. 31:1898–1902. 1995. View Article : Google Scholar | |
|
Kärnell R, von Schoultz E, Hansson LO, Nilsson B, Arstrand K and Kagedal B: S 100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res. 7:393–399. 1997.PubMed/NCBI | |
|
Henze G, Dummer R, Joller-Jemelka HI, Boni R and Burg G: Serum S 100-a marker for disease monitoring in metastatic melanoma. Dermatology. 194:208–212. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Krähn G, Kaskel P, Sander S, et al: S 100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 21:1311–1316. 2001.PubMed/NCBI | |
|
Hauschild A, Engel G, Brenner W, et al: Predictive value of serum S 100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol. 140:1065–1071. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Bosserhoff AK, Kaufmann M, Kaluza B, et al: Melanoma inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 57:3149–3153. 1997.PubMed/NCBI | |
|
Bosserhoff AK, Hein R, Bogdahn U, et al: Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem. 271:490–495. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Bosserhoff AK, Dreau D, Hein R, et al: Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma. Recent Results. Cancer Res. 158:158–168. 2001.PubMed/NCBI | |
|
Dietz UH and Sandell LJ: Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. J Biol Chem. 271:3311–3316. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Bosserhoff AK and Buettner R: Expression, function and clinical relevance of MIA (melanoma inhibitory activity). Histol Histopathol. 17:289–300. 2002.PubMed/NCBI | |
|
Bosserhoff AK, Moser M, Hein R, et al: In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers. J Pathol. 187:446–454. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Koehler MR, Bosserhoff A, von Beust G, Bauer A, Blesch A, Buettner R, Schlegel J, Bogdahn U and Schmid M: Assignment of the human melanoma inhibitory activity gene (MIA) to 19q13.4 by fluorescence in situ hybridization (FISH). Genomics. 35:264–267. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Bosserhoff AK, Lederer M, Kaufmann M, et al: MIA, a novel serum marker for progression of malignant melanoma. Anticancer Res. 19:2691–2693. 1999.PubMed/NCBI | |
|
Kelley MC, Gupta RK, Hsueh EC, Yee R, Stern S and Morton DL: Tumor associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I–III melanoma. J Clin Oncol. 19:1176–1182. 2001.PubMed/NCBI | |
|
Faries MB, Gupta RK, Ye X, et al: A comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients. Cancer Invest. 25:285–293. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Tsioulias G, Gupta RK, Tisman G, et al: Serum TA90 antigen-antibody complex as a surrogate marker of the efficacy of a polyvalent allogeneic whole-cell vaccine (Cancer-Vax) in melanoma. Ann Surg Oncol. 8:198–203. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
DiFronzo L, Gupta RK, Essner R, et al: Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol. 20:32422002. | |
|
Jones RC, Kelley MC, Gupta RK, et al: Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Ann Surg Oncol. 3:437–445. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Chung M, Gupta RK, Hsueh E, et al: Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J Clin Oncol. 21:313–319. 2003. View Article : Google Scholar | |
|
Kunter U, Buer J, Probst M, et al: Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst. 88:590–594. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Smith B, Selby P, Southgate J, et al: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet. 338:1227–1229. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Mellado B, Gutierrez L, Castel T, et al: Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res. 5:1843–1848. 1999. | |
|
Mellado B, Colomer D, Castel T, et al: Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol. 14:2091–2097. 1996. | |
|
Schittek B, Bodingbauer Y, Ellwanger U, et al: Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of melanoma. Br J Dermatol. 141:30–36. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Koyanagi K, Kuo C, Nakagawa T, Mori T, Ueno H, Lorico AR Jr, Wang HJ, Hseuh E, O’Day SJ and Hoon DS: Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem. 51:981–988. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Matsuzaki Y, Hashimoto S, Fujita T, Suzuki T, Sakurai T, Matsushima K and Kawakami Y: Systematic identification of human melanoma antigens using serial analysis of gene expression (sage). J Immunother. 28:10–19. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Reynolds SR, Albrecht J, Shapiro RL, Roses DF, Harris MN, Conrad A, Zeleniuch-Jacquotte A and Bystryn JC: Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res. 9:1497–1502. 2003.PubMed/NCBI | |
|
Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K and der Maase H: Elevated serum level of ykl-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 106:1130–1139. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Malinda KM, Ponce L, Kleinman HK, Shackelton LM and Millis AJ: Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res. 250:168–173. 1999. View Article : Google Scholar | |
|
Schmidt H, Johansen JS, Sjoegren P, et al: Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol. 24:798–804. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Vergilis IJ, Szarek M, Ferrone S and Reynolds SR: Presence and prognostic significance of melanoma-associated antigens Cyt-Maa and Hmw-Maa in serum of patients with melanoma. J Invest Dermatol. 125:526–531. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Reynolds SR, Vergilis IJ, Szarek M, Ferrone S and Bystryn J: Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy? Int J Cancer. 119:157–161. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Brown JP, Hewick RM, Hellstrom I, Hellstrom KE, Doolittle RF and Dreyer WJ: Human melanoma associated antigen p97 is structurally and functionally related to transferrin. Nature. 296:171–173. 1982. View Article : Google Scholar : PubMed/NCBI | |
|
Richardson DR: The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell. Eur J Biochem. 267:1290–1298. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Brown JP, Nishiyama K, Hellstrom I and Hellstrom KE: Structural characterization of human melanoma-ssociated antigen p97 with monoclonal antibodies. J Immunol. 127:539–546. 1981.PubMed/NCBI | |
|
Sekyere EO, Dunn LL and Richardson DR: Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and human. Biochim Biophys Acta. 1722:131–142. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Graeven U, Rodeck U, Karpinski S, Jost M, Philippou S and Schmiegel W: Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res. 61:7282–7290. 2001.PubMed/NCBI | |
|
Sala R, Jefferies WA, Walker B, et al: The human melanoma associated protein melanotransferrin promotes endothelial cell migration and angiogenesis in vivo. Eur J Cell Biol. 81:599–607. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Dunn LL, Sekyere EO, Suryo Rahmanto Y and Richardson DR: The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. Carcinogenesis. 27:2157–2169. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Levy C, Khaled M and Fisher DE: MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med. 12:406–414. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Garraway LA, Widlund HR, Rubin MA, et al: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 436:117–122. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Koyanagi K, O’Day SJ, Gonzalez R, et al: Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res. 12:1137–1143. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hoek KS, Schlegel NC, Bradfford P, et al: Metastatic potential of melanomas defined by specific gene expression profiles with no B-RAF signature. Pigment Cell Res. 19:290–302. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Maresh GA, Marken JS, Neubauer M, et al: Cloning and expression of the gene for the melanoma-associated ME20 antigen. DNA Cell Biol. 13:87–95. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Scheibenbogen C, Weyers I, Ruiter D, et al: Expression of gp100 in melanoma metastases resected before or after treatment with IFN alpha and IL-2. J Immunother Emphasis Tumor Immunol. 19:375–380. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Schrader AJ, Probst-Kepper M, Grosse J, Kunter U, Schenk F, Franzke A, Atzpodien J and Buer J: Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells. Melanoma Res. 10:355–362. 2000. View Article : Google Scholar | |
|
Mahmoud FA and Rivera NI: The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 4:250–255. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Castell JV, Gómez-Lechón MJ, David M, Andus T, Geiger T, Trullenque R, Fabra R and Heinrich PC: Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 242:237–239. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Deichmann M, Kahle B, Moser K, Wacker J and Wu K: Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer. 91:699–702. 2004. | |
|
Mouawad R, Benhammouda A, Antoine EC, Borel C, Weil M, Khayat D and Soubrane C: Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res. 2:1405–1409. 1996.PubMed/NCBI | |
|
Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, Montero F, Joyeux I, Pouillart P and Fridman WH: Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer. 69:911–913. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Deichmann M, Benner A, Jackel A, Bock M, Waldmann V and Naher H: Elevated interleukin-6 serum levels indicate progressive disease in metastasized malignant melanoma. J Exp Clin Cancer Res. 19:301–307. 2000. | |
|
Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V and Douillard JY: Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol. 14:1697–1703. 1996.PubMed/NCBI | |
|
Jacob K, Sollier C and Jabado N: Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev Proteonomics. 4:741–756. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Mocellini S, Del Fiore P, Guarnieri L, et al: Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer. 111:741–745. 2004. View Article : Google Scholar | |
|
Ulmer A, Schmidt-Kittler O, Fischer J, Ellwanger U, Rassner G, Riethmüller G, Fierlbeck G and Klein CA: Immunomagnetic enrichment, genomic characterization and prognostic impact of circulating melanoma cells. Clin Cancer Res. 10:531–537. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Keilholz U, Martus P, Punt CJ, et al: Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: Second analysis of a randomized EORTC Melanoma Group trial comparing interferon-2a and interleukin-2 (IL-2) with or without cisplatin. Eur J Cancer. 38:1501–1511. 2002. | |
|
Linette GP, Carlson JA, Slominski A, Mihm MC and Ross JS: Biomarkers in melanoma: stage III and IV disease. Expert Rev Mol Design. 5:65–74. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Mellado B, Del Carmen V, Colomer D, et al: Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J Clin Oncol. 20:4032–4039. 2002. View Article : Google Scholar : PubMed/NCBI |
